Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dikla Czaczkes Akselbrad
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 72
- Beta
- 1.43
- Country
- IL
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -10.98
Financials
Net Income
$-5.75MEBITDA
$-8.47MFree Cash Flow
—EPS (diluted)
$-0.24Shares Outstanding (diluted)
23.68M+2608.7%Operating Expenses
$8.47MCash & Debt
$15.70MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-34.17M | $-2.09 |
| 2024 | $0.00 | $-29.02M | $-4.91 |
| 2023 | $0.00 | $-23.86M | $-16.99 |
| 2022 | $0.00 | $-39.52M | $-61.20 |
| 2021 | $0.00 | $-40.71M | $-67.80 |
| 2020 | $0.00 | $-35.32M | $-4.48 |
| 2019 | $0.00 | $-6.91M | $-15.03 |
| 2018 | $0.00 | $5.92M | $26.70 |
| 2017 | $0.00 | $-54.49M | $-370.58 |
| 2016 | $0.00 | $-11.39M | $-77.48 |
| 2015 | $0.00 | $-8.22M | $-37.62 |
| 2013 | $0.00 | $-3.88M | $-39.58 |
| 2012 | $0.00 | $-1.79M | $-8.08 |
Valuation
PYPDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+200.00%Social Signal Score
Mentions (14)
- Newsmarketbeat.com·11d ago·Neutral
What PolyPid (PYPD) Said on Its Q3 Earnings Call PolyPid NASDAQ: PYPD is approaching a Nov. 28 U.S. regulatory decision on D-PLEX100, its experimental product for preventing surgical site infections in patients undergoing colorectal surgery, while preparing with partner Azurity Pharmaceuticals for a potential launch in early 2027.
View source ↗ - Newsglobenewswire.com·11d ago·Neutral
PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results D-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing
View source ↗ - Newsseekingalpha.com·18d ago·Neutral
PolyPid: Strong Phase 3 Data Support A Buy Ahead Of November's FDA Decision PolyPid Ltd. is rated BUY with a $7.25 price target, offering 35% upside ahead of the November 28, 2026 FDA decision on D-PLEX100. SHIELD II Phase 3 data showed clinically meaningful reductions in surgical site infections, but prior SHIELD I failure and regulatory risks temper conviction. The Azurity partnership secures commercialization in the U.S. and Canada, with $320 million in potential milestone payments and mid-te
View source ↗ - Newsmarketbeat.com·24d ago·Neutral
PolyPid Targets 2027 D-PLEX100 Launch, Unveils Diabetic Foot Infection Program PolyPid NASDAQ: PYPD outlined plans to expand its commercial and development strategy through 2030 at an investor day, as the company approaches a November 28, 2026, FDA action date for its D-PLEX100 surgical-site infection prevention product candidate.
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections Company to host virtual Investor Day today at 11:30 AM ET, featuring key opinion leader Warren S. Joseph, DPM, FIDSA All scheduled FDA interactions on track and aligned with D-PLEX ₁₀₀ November 28, 2026 PDUFA goal date PolyPid introduces PD01B, a new product candidate targeting hyper-localized, controlled-release antibiotic treatment of diabetic
View source ↗ - Newsglobenewswire.com·32d ago·Negative
PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026 Analysis demonstrates a lower bacterial burden in breakthrough surgical-site infections, with similar proportions of multidrug-resistant organisms between treatment groups Analysis demonstrates a lower bacterial burden in breakthrough surgical-site infections, with similar proportions of multidrug-resistant organisms between treatment groups
View source ↗ - Newsglobenewswire.com·38d ago·Positive
PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026 Management to outline ‘PolyPid 2030', the Company's long-term vision and pipeline strategy Event to feature Warren S. Joseph, DPM, FIDSA, a nationally recognized specialist in lower extremity infectious diseases Petach Tikva, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd.
View source ↗ - Newsmarketbeat.com·49d ago·Positive
PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data PolyPid NASDAQ: PYPD is approaching a November 28 PDUFA date for D-PLEX100, its lead product candidate for preventing surgical site infections in patients undergoing colorectal surgery, Chief Executive Officer Dikla Czaczkes Akselbrad said during the Lytham Partners Fall 2026 Investor Conference.
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
European Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX₁₀₀ PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month
View source ↗ - Newsglobenewswire.com·52d ago·Positive
…ommercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that PolyPid and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX…
View source ↗ - Newsglobenewswire.com·68d ago·Neutral
PolyPid Announces Participation in Upcoming Fall Investor Conferences PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in the following upcoming investor conferences:
View source ↗ - Newsseekingalpha.com·102d ago·Positive
PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·102d ago·Negative
PolyPid Q2 Earnings Call Highlights PolyPid NASDAQ: PYPD said its second-quarter 2026 was marked by the FDA's acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada.
View source ↗ - Newsglobenewswire.com·102d ago·Neutral
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance
View source ↗
Earnings
Wed, Feb 10(in 3 months)
Consensus estimate $-0.13 per share
Typical surprise +7.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 11$-0.24 vs $0.91miss
- Wed, Aug 12$-0.35 vs $-0.38beat
- Wed, May 13$-0.35 vs $-0.47beat
- Wed, Feb 11$-0.41 vs $-0.34miss
- Wed, Nov 12$-0.37 vs $-0.54beat
- Wed, Aug 13$-0.78 vs $-0.53miss
Estimates and results for PYPD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PYPD officers and directors.
No open-market trades in the recent filings. All 84 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PYPD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
